


Integrity: Uma ferramenta analítica para acelerar a Pesquisa e Desenvolvimento de Fármacos


Sergio Delarcina Júnior

As etapas de desenvolvimento de novos fármacos

Drug Discovery




Taxa de sucesso de obtenção de um fármaco entre compostos bioativos




Informação x Big Data

Publicações do tema "CRISPR - Cas9" - WoS




O aparecimento de ferramentas de busca e análise de informação facilita a priorização e o acesso a informações relevantes

Soluções em Life Sciences




Integrity: Overview

- Informações Integradas
- Atualizações diárias
- Informações curadas manualmente



	Drugs & Biologics
	Genes & Targets
	Organic Synthesis
	Experimental Pharmacology
	Experimental Models
	Pharmacokinetics
	Drug-Drug Interactions
	Clinical Studies
	Organizations
	Literature
	Patents
	Disease Briefings
	Biomarkers

Construção da Informação no Integrity





EQUIPE EDITORIAL:


- Equipe dedicada de + 200 editores
- Todos eles PhDs em ciências da vida como medicina, biologia molecular e bioquímica
- Rede de + 600 líderes de opinião

1. Disease Briefings

- Etiologia/Fisiopatologia
- Pipeline de fármacos em desenvolvimento.
- Alvos potenciais para intervenção farmacológica.



2. Genes & Targets



- Avaliação das vias canônicas de alvos e sinalização celular.
- Compreensão geral das funcionalidades de cada alvo.
- Seleção de fármacos e biológicos potenciais.

3. Experimental Pharmacology & 4. Experimental Models

- Avaliação comparative dos fármacos e biológicos mais promissores.
- Informações iniciais para qSAR.
- Informações sobre Material e Métodos para métodos in vitro e pré-clínicos

Experimental Pharmacology Mean / Median

Apply Filters Filter by Value Range Unify - Convert Show normalized units Sorted by relevance Showing 1-1 of 1 Experimental Pharmacology records for Pharmacological Activ...

Drug Name	System	Experimental Activity	Pharmacological Activity	Material/Experimental Model	Method	Parameter	Value	Source
CVD-0013943		Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) remission/reduction, IN VITRO	Coronavirus (COVID-19; 2019-nCoV) (B.1.135 variant), antiviral activity			IC-50	469 nM	Literature

Filter by Value Range

Please select a parameter and unit. To optimize your results, please consider the option to Unify-Convert your parameters and units before you proceed with filtering by value range.

Select Parameter: EC-50 (24) Select Unit: M (24)

Select all / Clear all

<input type="checkbox"/>	1x10 E-12 to 1x10 E-11
<input type="checkbox"/>	1x10 E-11 to 1x10 E-10
<input type="checkbox"/>	1x10 E-10 to 1x10 E-9
<input type="checkbox"/>	1x10 E-9 to 1x10 E-8
<input type="checkbox"/>	1x10 E-8 to 1x10 E-7
<input type="checkbox"/>	1x10 E-7 to 1x10 E-6
<input type="checkbox"/>	1x10 E-6 to 1x10 E-5
<input type="checkbox"/>	1x10 E-5 to 1x10 E-4


5. Pharmacokinetics

Pharmacokinetics

Apply Filters Sorted by relevance Showing 1-25

Parameter 1 x


<input type="checkbox"/>	Administered Product	Dosage	Measured Product	Parameter	Value	Compartment
<input type="checkbox"/>	MET Azilsartan medoxomil potassium	60 mg	Azilsartan	AUC	22.97 mg·h/l	Plasma
<input type="checkbox"/>	MET Azilsartan medoxomil potassium	40 mg	Azilsartan	AUC	17.36 mg·h/l	Plasma
<input type="checkbox"/>	MET Azilsartan medoxomil potassium	60 mg	Azilsartan	AUC	16.32 mg·h/l	Plasma



- Avaliação de parâmetros de ADME para aprimoramento de fármacos.
- Compreensão do metabolismo primário e de segunda passagem.
- Metodologia analítica completa

6. Clinical Trials

- Informações sobre o pipeline de lançamentos de produtos em fase clínica
- Informações sobre resultados e objetivos esperados.
- Identificação de biomarcadores empregados.



The screenshot displays a web interface for 'Clinical Studies'. At the top, it shows 'Showing 1-25 of 974 Clinical Studies records for Intervention Type: Drug therapy...'. Below this, there is a filter for 'Phase 1'. The main content is a table with the following columns: Study Name, Study Design, Intervention Type, Condition, Identifier (Phase), Population Number, and Drugs. Two study entries are visible:

<input type="checkbox"/>	Study Name	Study Design	Intervention Type	Condition	Identifier (Phase)	Population Number	Drugs
<input type="checkbox"/>	Renzapride in irritable bowel syndrome: The NCT00607971 study	Multicenter Open	Drug therapy	Irritable bowel syndrome	NCT00607971 (Phase 3 Clinical)	900	1
<input type="checkbox"/>	Rimonabant in hepatic steatosis and type 2 diabetes: The NCT00577148 study	Double-blind Multicenter	Drug therapy	Diabetes type 2 Hepatic steatosis	NCT00577148 (Phase 3 Clinical)	720	1

7. Patents

- Patentes completas obtidas em 7 escritórios de patentes.
- Fórmulas de Markush e estruturas químicas resolvidas e associadas a nomenclatura de fármacos.
- Possibilidade de filtro por área de invenção para prospecção de soluções tecnológicas empregadas.



Patents

Apply Filters Sorted by relevance Showing 1-9 of 9 Patents records for Subject Matter:

Patent Number	Patent Title	Applicant	Publication Date	Subject Matter	Condition
<input type="checkbox"/> CN112526143	Application of myeloid cell trigger receptor 2 as new type coronavirus pneumonia diagnosis or treatment target point	Fifth Affiliated Hospital Sun Yat-Sen University	Mar 19, 2021	Biomarkers Targets	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
<input type="checkbox"/> WO2005035712 US7618802 US2006240530 RU2005140230	Methods and compositions for infectious cDNA of SARS coronavirus	University of North Carolina at Chapel Hill	Apr 21, 2005	Targets	Severe acute respiratory syndrome coronavirus (SARS-CoV) infection
<input type="checkbox"/> WO2005035712 US7618802 US2006240530 RU2005140230	Methods and compositions for infectious cDNA of SARS coronavirus	University of North Carolina at Chapel Hill	Apr 21, 2005	Targets	Severe acute respiratory syndrome coronavirus (SARS-CoV) infection

Integrity: como se cadastrar*

Passo 1: Em rede com IP pertencente ao ambiente CAPES, acessar o Portal de Periódicos da CAPES (<http://www.periodicos.capes.gov.br/>) e em “BASE” procurar por “Integrity”. Deverá funcionar também através da VPN, PROXY, ou rede CAFE da Universidade.



* Obs.: Todos os usuários do Integrity terão acesso ao CDDI

Passo 2: Selecione o Link para ser redirecionado ao site de Primeiro Acesso do Integrity

Inmetro. Acervo Digital 🇧🇷	Repositórios Institucionais , Textos completos	
Inorganic Crystal Structure Database : ICSD (BDEC)	Obras de Referência	
Institution of Civil Engineers - ICE	Textos completos	
Instituto Brasileiro de Geografia e Estatística (IBGE) 🇧🇷	Estatísticas	
Instituto Brasileiro de Informação em Ciência e Tecnologia (IBICT). Repositório Institucional Di	Repositórios Institucionais	
Instituto Brasiliense de Direito Público (IDP). Biblioteca Digital 🇧🇷	Repositórios Institucionais	
Instituto de Pesca, São Paulo. Dissertações Defendidas 🇧🇷	Teses e Dissertações	
Instituto de Pesquisas e Estudos Florestais (IPEF). Teses, Dissertações, Monografias Florestais 🇧🇷	Teses e Dissertações	
Instituto de Zootecnia (São Paulo). Dissertações defendidas 🇧🇷	Teses e Dissertações	
Instituto Nacional de Estudos e Pesquisas Educacionais Anísio Teixeira (Inep). Publicações 🇧🇷	Livros , Textos completos	
Instituto Tecnológico da Aeronáutica (ITA). Biblioteca Digital 🇧🇷	Teses e Dissertações	
Integrity (Clarivate Analytics)	Obras de Referência , Ferramenta de Busca	
International Encyclopedia of the Social and Behavioral Sciences (Elsevier)	Obras de Referência	



**Passo 3: Selecionar o campo
“Self-Register” em “First-
time Users”**

Welcome

Registered Users

If you already have a User Name and Password to use Thomson Reuters Integrity, enter them here and click Login

User Name

Password **Login**

Forgotten login details? Please [click here](#)

Use of this service is offered to Authorized Users on the condition that they accept the [Terms of Use](#)

First-time Users

If your company/institution has licensed Thomson Reuters Integrity under the self-registration mode, click here to register **Self-Register**

More Information

Access to Thomson Reuters Integrity is available to licensed users. To request more information about this product, [click here](#)



© 2017 Clarivate Analytics.
All rights reserved.

Passo 4: Preencher o registro com um e-mail válido de uso frequente para uso futuro do “keep me posted” e para atualizações do Integrity. Por gentileza especificar a instituição a qual pertence. Por exemplo: Universidade X /Faculdade Y/ Departamento Z. Ao final clicar em “Send”.

WELCOME TO THOMSON REUTERS INTEGRITY - REGISTER YOUR DETAILS

To begin your *Integrity* session please update your personal details below and then click **Send**

This will allow us to verify your account, and ensure you get the most out of Integrity. Once you have completed this registration form you will not be asked for these details when you next log in.

All fields are compulsory - please complete this form in **ENGLISH** only

Login Details

E-mail	<input type="text" value="contato@email.com"/>
Confirm email	<input type="text" value="contato@email.com"/>
User Name	<input type="text" value="Contato"/>
Password	<input type="password" value="*****"/>
Confirm Password	<input type="password" value="*****"/>

* Wrong Password Format


Contact Details

Salutation	<input type="text" value="Dr."/>
First Name	<input type="text" value="Contato"/>
Last Name	<input type="text" value="Contato"/>

Role & Company

Job Role	<input type="text" value="Scientist / Dept. Member"/>
Job Area	<input type="text" value="Biology"/>

First Name	<input type="text" value="Contato"/>
Last Name	<input type="text" value="Contato"/>
Role & Company	
Job Role	<input type="text" value="Scientist / Dept. Member"/>
Job Area	<input type="text" value="Biology"/>
Specific Job Area	<input type="text" value="Cell Biologist"/>
Company/Institution	<input type="text" value="Universidade"/>
City	<input type="text" value="Manaus"/>
Postcode	<input type="text" value="000000"/>
Country	<input type="text" value="Brazil"/>
Language	<input type="text" value="ENGLISH"/>
Telephone Number	<input type="text" value="55-11-00000"/>
Please send me periodic updates on <i>Integrity</i> including new release notices and training schedules. <input checked="" type="radio"/> Yes <input type="radio"/> No	
I agree that my details will be used in accordance with the Privacy Policy , including sharing my details with other parts of the Science business of Thomson Reuters to enable the above updates to be sent. <input checked="" type="radio"/> Yes <input type="radio"/> No	
* I understand my details will be shared with the wider Thomson Reuters business, but will not be passed to any third parties.	
By clicking "Send", you agree and consent to the Privacy Policy , including the reception of electronic communications from the Science business of Thomson Reuters.	
<input type="button" value="Reset"/>	<input type="button" value="Send"/>



Obrigado